Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Results of the ECOG E1900 Trial in Younger Adults with AML Using an Event Free Survival Endpoint Are Concordant with Results Based on Overall Survival: Potential for a Surrogate Endpoint to Facilitate Rapid Approval of Therapies in AML

Marlise R. Luskin, MD, Ju-Whei Lee, PhD, Hugo F. Fernandez, MD, Hillard M. Lazarus, Jacob M. Rowe, MD, Martin S. Tallman, MD, Elisabeth M. Paietta, PhD, Mark Litzow, Omar Abdel-Wahab, MD, Jay P. Patel, Ross L. Levine, MD, Zhuoxin Sun, PhD, Selina M. Luger, MD

Blood (2014) 124 (21): 2599.

https://doi.org/10.1182/blood.V124.21.2599.2599

Published: 2014

Journal Articles

Telomere Length Recovery Strongly Predicts Overall Survival in Acute Promyelocytic Leukemia

Muhamed Baljevic, MD, Bogdan Dumitriu, MD, Ju-Whei Lee, PhD, Elisabeth Paietta, PhD, Janis Racevskis, Christina Chen, BS, Eytan M. Stein, Robert E Gallagher, MD, Jacob M. Rowe, MD, Frederick R. Appelbaum, MD, Bayard L. Powell, MD, Richard A. Larson, Neal S. Young, MD, Martin S. Tallman, MD

Blood (2014) 124 (21): 2375.

https://doi.org/10.1182/blood.V124.21.2375.2375

Published: 2014

Journal Articles

Effect of Genetic Profiling on Prediction of Therapeutic Resistance and Survival in Adult Acute Myeloid Leukemia

Roland B. Walter, MD PhD MS, Megan Othus, PhD, Elisabeth M. Paietta, PhD, Janis Racevskis, PhD, Hugo F Fernandez, MD, Ju-Whei Lee, PhD, Zhuoxin Sun, PhD, Martin S. Tallman, MD, Jay P. Patel, Mithat Gönen, PhD, Omar Abdel-Wahab, MD, Ross L Levine, MD, Elihu H. Estey, MD

Blood (2014) 124 (21): 941.

https://doi.org/10.1182/blood.V124.21.941.941

Published: 2014

Journal Articles

Determinants of Fatal Bleeding during Induction Therapy for Acute Promyelocytic Leukemia in the ATRA Era

Simon Mantha, MD MPH, Debra Goldman, MS, Sean M. Devlin, PhD, Ju-Whei Lee, PhD, Diana Zannino, BSc, MSc, Dan Douer, MD, Harry J Iland, MBBS FRACP FRCPA, Mark R. Litzow, MD, Eytan M. Stein, Frederick Appelbaum, MD, Richard A. Larson, Jacob M. Rowe, MD, Martin S. Tallman, MD

Blood (2014) 124 (21): 948.

https://doi.org/10.1182/blood.V124.21.948.948

Published: 2014

Journal Articles

High Dose Daunorubicin Improves Survival in AML up to Age 60, Across All Cytogenetic Risk Groups Including Patients with Unfavorable Cytogenetic Risk, and FLT3-ITD Mutant AML: Updated Analyses from Eastern Cooperative Oncology Trial E1900

Marlise R. Luskin, MD, Ju-Whei Lee, PhD, Hugo F Fernandez, MD, Hillard M. Lazarus, Jacob M. Rowe, MD, Martin S. Tallman, MD, Elisabeth M. Paietta, PhD, Mark Litzow, Omar Abdel-Wahab, MD, Jay P. Patel, Ross L. Levine, MD, Zhuoxin Sun, PhD, Selina M. Luger, MD

Blood (2014) 124 (21): 373.

https://doi.org/10.1182/blood.V124.21.373.373

Published: 2014

NARROW

Results of the ECOG E1900 Trial in Younger Adults with AML Using an Event Free Survival Endpoint Are Concordant with Results Based on Overall Survival: Potential for a Surrogate Endpoint to Facilitate Rapid Approval of Therapies in AML

Telomere Length Recovery Strongly Predicts Overall Survival in Acute Promyelocytic Leukemia

Effect of Genetic Profiling on Prediction of Therapeutic Resistance and Survival in Adult Acute Myeloid Leukemia

Determinants of Fatal Bleeding during Induction Therapy for Acute Promyelocytic Leukemia in the ATRA Era

High Dose Daunorubicin Improves Survival in AML up to Age 60, Across All Cytogenetic Risk Groups Including Patients with Unfavorable Cytogenetic Risk, and FLT3-ITD Mutant AML: Updated Analyses from Eastern Cooperative Oncology Trial E1900

Email alerts

ASH Publications

American Society of Hematology

Results of the ECOG E1900 Trial in Younger Adults with AML Using an Event Free Survival Endpoint Are Concordant with Results Based on Overall Survival: Potential for a Surrogate Endpoint to Facilitate Rapid Approval of Therapies in AML

Telomere Length Recovery Strongly Predicts Overall Survival in Acute Promyelocytic Leukemia

Effect of Genetic Profiling on Prediction of Therapeutic Resistance and Survival in Adult Acute Myeloid Leukemia

Determinants of Fatal Bleeding during Induction Therapy for Acute Promyelocytic Leukemia in the ATRA Era

High Dose Daunorubicin Improves Survival in AML up to Age 60, Across All Cytogenetic Risk Groups Including Patients with Unfavorable Cytogenetic Risk, and FLT3-ITD Mutant AML: Updated Analyses from Eastern Cooperative Oncology Trial E1900

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only